Drugs.com - Clinical Trials

FDA Grants Fast Track Designation to PleoPharma, Inc's Investigational New Drug, PP-01, for the Mitigation of Cannabis Withdrawal Symptoms in Patients With Cannabis Use Disorder

PHOENIXVILLE, Pa., Feb. 13, 2025 /PRNewswire/ -- PleoPharma, Inc., a privately held company focused on finding treatments for cannabis related health issues, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track...

Feb 17, 2025 - 20:49
 0
FDA Grants Fast Track Designation to PleoPharma, Inc's Investigational New Drug, PP-01, for the Mitigation of Cannabis Withdrawal Symptoms in Patients With Cannabis Use Disorder
PHOENIXVILLE, Pa., Feb. 13, 2025 /PRNewswire/ -- PleoPharma, Inc., a privately held company focused on finding treatments for cannabis related health issues, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track...
Read More

Tags:

Previous Article

Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lac...

Next Article

(Study) Manufacturing Workforce Engagement Study

Related Posts

Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer

Innovent Receives Second Fast Track Designation from th...

Feb 27, 2025  0

Zydus Announces USFDA Orphan Drug Designation to Usnoflast for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Zydus Announces USFDA Orphan Drug Designation to Usnofl...

Feb 9, 2025  0

Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy

Vertex Announces Results From Phase 2 Study of Suzetrig...

Feb 9, 2025  0